BlackRock’s Genocea Biosciences, Inc. GNCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-180,367
| Closed | -$225K | – | 6126 |
|
|
2022
Q1 | $225K | Sell |
180,367
-5,076
| -3% | -$5.53K | ﹤0.01% | 5081 |
|
|
2021
Q4 | $215K | Buy |
185,443
+4,452
| +2% | +$6.63K | ﹤0.01% | 5091 |
|
|
2021
Q3 | $347K | Buy |
180,991
+2,019
| +1% | +$3.97K | ﹤0.01% | 4855 |
|
|
2021
Q2 | $419K | Buy |
178,972
+35,685
| +25% | +$86K | ﹤0.01% | 4736 |
|
|
2021
Q1 | $388K | Buy |
143,287
+6,028
| +4% | +$17.8K | ﹤0.01% | 4644 |
|
|
2020
Q4 | $332K | Buy |
137,259
+2,192
| +2% | +$4.99K | ﹤0.01% | 4402 |
|
|
2020
Q3 | $309K | Sell |
135,067
-59,994
| -31% | -$157K | ﹤0.01% | 4339 |
|
|
2020
Q2 | $448K | Buy |
195,061
+45,261
| +30% | +$104K | ﹤0.01% | 4234 |
|
|
2020
Q1 | $258K | Sell |
149,800
-2,726
| -2% | -$5.51K | ﹤0.01% | 4185 |
|
|
2019
Q4 | $316K | Buy |
152,526
+67,757
| +80% | +$161K | ﹤0.01% | 4243 |
|
|
2019
Q3 | $245K | Buy |
84,769
+46,755
| +123% | +$160K | ﹤0.01% | 4298 |
|
|
2019
Q2 | $149K | Buy |
38,014
+13,018
| +52% | +$67.9K | ﹤0.01% | 4408 |
|
|
2019
Q1 | $118K | Buy |
24,996
+116
| +0.5% | +$574 | ﹤0.01% | 4353 |
|
|
2018
Q4 | $57K | Buy |
24,880
+144
| +0.6% | +$717 | ﹤0.01% | 4459 |
|
|
2018
Q3 | $155K | Sell |
24,736
-5,532
| -18% | -$29.2K | ﹤0.01% | 4376 |
|
|
2018
Q2 | $207K | Sell |
30,268
-464,776
| -94% | -$3.48M | ﹤0.01% | 4297 |
|
|
2018
Q1 | $4.16M | Buy |
495,044
+311,067
| +169% | +$2.58M | ﹤0.01% | 3474 |
|
|
2017
Q4 | $1.71M | Buy |
183,977
+1,477
| +0.8% | +$14.9K | ﹤0.01% | 3742 |
|
|
2017
Q3 | $2.13M | Buy |
182,500
+3,278
| +2% | +$124K | ﹤0.01% | 3690 |
|
|
2017
Q2 | $7.49M | Buy |
179,222
+143,126
| +397% | +$6.89M | ﹤0.01% | 3319 |
|
|
2017
Q1 | $1.76M | Buy |
+36,096
| New | +$1.41M | ﹤0.01% | 3696 |
|
|
2016
Q2 | – | Sell |
-100
| Closed | -$6K | – | 3871 |
|
|
2016
Q1 | $6K | Buy |
100
+40
| +67% | +$1.27K | ﹤0.01% | 3354 |
|
|
2015
Q4 | $3K | Hold |
60
| – | – | ﹤0.01% | 3287 |
|
|
2015
Q3 | $3K | Hold |
60
| – | – | ﹤0.01% | 3140 |
|
|
2015
Q2 | $7K | Buy |
+60
| New | +$5.57K | ﹤0.01% | 3025 |
|
Other funds holding GNCA
BlackRock's GNCA Position: Q2 2022 in Review
BlackRock sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 180,367 shares — an estimated $225K sold.
BlackRock first reported a position in GNCA in Q2 2015 and held it in 25 quarters. The position peaked at $7.49M in Q2 2017. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.
- BlackRock reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
- BlackRock sold 180,367 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $225K.
- BlackRock first reported a position in Genocea Biosciences, Inc. in Q2 2015 and held it in 25 quarters.
- BlackRock's Genocea Biosciences, Inc. position peaked at $7.49M in Q2 2017.
- 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.
Based on BlackRock's 13F filing for Q2 2022, filed 12 Aug 2022.